Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus
Abstract
The central nervous system (CNS) is a likely reservoir of human immunodeficiency virus (HIV), vulnerable to viral rebound, inflammation, and clinical changes upon stopping antiretroviral therapy (ART). It is critical to evaluate the CNS safety of studies using analytic treatment interruption (ATI) to assess HIV remission.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 11, 2020
- Source ID
- 10.1093/cid/ciaa1344
Entities
People
- Bonnie M. Slike
- Camilla Muccini
- Carlo Sacdalan
- Donn J. Colby
- Eugène Kroon
- Frank Tomaka
- Jintana Intasan
- Jintanat Ananworanich
- Joanna Hellmuth
- Khunthalee Benjapornpong
- Linda L. Jagodzinski
- Mark de Souza
- Merlin L Robb
- Michal Sarnecki
- Napapon Sailasuta
- Nelson Michael
- Netsiri Dumrongpisutikul
- Nitiya Chomchey
- Nittaya Phanuphak
- Phillip Chan
- Praphan Phanuphak
- Robert Paul
- Sandhya Vasan
- Serena Spudich
- Shelly J. Krebs
- Somporn Tipsuk
- Suwanna Puttamaswin
- Trevor A Crowell
- Victor G Valcour
- Vishal Samboju
Organizations
- Chulalongkorn University
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Janssen Pharmaceutica
- Janssen Vaccines
- Merck & Co.
- National Institute of Mental Health
- National Institutes of Health
- Thai Red Cross Society
- United States Department of Defense
- University of Amsterdam
- University of California
- University of California, San Francisco
- University of Hawaiʻi System
- University of Missouri–St. Louis
- ViiV Healthcare
- Walter Reed Army Institute of Research
- Yale University